+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Alzheimer's Therapeutics Market by Drug Class (Cholinesterase Inhibitors, NMDA [N-methyl-D-aspartate] Receptor Antagonist), Type (Medication, NMDA Receptor Antagonist), Distribution - Forecast 2024-2030

  • PDF Icon

    Report

  • 196 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5305530
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Alzheimer’s Therapeutics Market size was estimated at USD 6.14 billion in 2023, USD 6.66 billion in 2024, and is expected to grow at a CAGR of 8.63% to reach USD 10.96 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Alzheimer’s Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alzheimer’s Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Alzheimer’s Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AC Immune SA, Acadia Pharmaceuticals Inc., Alnylam Pharmaceuticals, Inc., AlzeCure Pharma AB, Alzheon, Inc., AstraZeneca PLC, Biogen Inc., Cassava Sciences, Inc., Cognition Therapeutics, Inc., Corium, Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Grifols S.A., H. Lundbeck A/S, Luye Pharma Group Ltd., Merz Pharma GmbH & Co. KGaA, NeuroVision Imaging, Inc., Novartis AG, Oryzon Genomics, S.A., Pfizer, Inc., Siemens Healthcare GmbH, Synaptogenix, Inc., TauRx Pharmaceuticals Ltd., and VTV Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Alzheimer’s Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Cholinesterase Inhibitors
    • NMDA [N-methyl-D-aspartate] Receptor Antagonist
  • Type
    • Medication
      • Cholinesterase inhibitors
      • Donepezil
      • Galantamine
      • Rivastigmine
    • NMDA Receptor Antagonist
  • Distribution
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Alzheimer’s Therapeutics Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alzheimer’s Therapeutics Market?
  3. What are the technology trends and regulatory frameworks in the Alzheimer’s Therapeutics Market?
  4. What is the market share of the leading vendors in the Alzheimer’s Therapeutics Market?
  5. Which modes and strategic moves are suitable for entering the Alzheimer’s Therapeutics Market?

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Purchase of this report includes 1 year online access with quarterly updates

Purchase of this report includes 1 year online access with quarterly updates

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Alzheimer’s Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of Alzheimer’s among population
5.1.1.2. Growing development and availability of pipeline drugs
5.1.1.3. Improved healthcare facilities and technologies for early detection of Alzheimer’s
5.1.2. Restraints
5.1.2.1. Capital intensive treatment for Alzheimer’s
5.1.3. Opportunities
5.1.3.1. Intense research and development with inclusion of cloud-based cognitive systems and artificial intelligence
5.1.3.2. Development of novel biomarkers and emerging regenerative therapies
5.1.4. Challenges
5.1.4.1. Stringent drug approval processes
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Alzheimer’s Therapeutics Market, by Drug Class
6.1. Introduction
6.2. Cholinesterase Inhibitors
6.3. NMDA [N-methyl-D-aspartate] Receptor Antagonist
7. Alzheimer’s Therapeutics Market, by Type
7.1. Introduction
7.2. Medication
7.3.1. Cholinesterase inhibitors
7.3.2. Donepezil
7.3.3. Galantamine
7.3.4. Rivastigmine
7.3. NMDA Receptor Antagonist
8. Alzheimer’s Therapeutics Market, by Distribution
8.1. Introduction
8.2. Online Pharmacies
8.3. Retail Pharmacies
9. Americas Alzheimer’s Therapeutics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Alzheimer’s Therapeutics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Alzheimer’s Therapeutics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
12.3.1. New Product Launch & Enhancement
12.3.1.1. The Next Phase of Alzheimer’s Therapeutics with Alzstatin ACD680
12.3.1.2. Alzecure Selects CD and Enters Next Development Phase with Alzstatin ACD680 against Alzheimer’s
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie Inc.
13.1.2. AC Immune SA
13.1.3. Acadia Pharmaceuticals Inc.
13.1.4. Alnylam Pharmaceuticals, Inc.
13.1.5. AlzeCure Pharma AB
13.1.6. Alzheon, Inc.
13.1.7. AstraZeneca PLC
13.1.8. Biogen Inc.
13.1.9. Cassava Sciences, Inc.
13.1.10. Cognition Therapeutics, Inc.
13.1.11. Corium, Inc.
13.1.12. Eisai Co., Ltd.
13.1.13. Eli Lilly and Company
13.1.14. F. Hoffmann-La Roche Ltd.
13.1.15. Grifols S.A.
13.1.16. H. Lundbeck A/S
13.1.17. Luye Pharma Group Ltd.
13.1.18. Merz Pharma GmbH & Co. KGaA
13.1.19. NeuroVision Imaging, Inc.
13.1.20. Novartis AG
13.1.21. Oryzon Genomics, S.A.
13.1.22. Pfizer, Inc.
13.1.23. Siemens Healthcare GmbH
13.1.24. Synaptogenix, Inc.
13.1.25. TauRx Pharmaceuticals Ltd.
13.1.26. VTV Therapeutics
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. ALZHEIMER’S THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ALZHEIMER’S THERAPEUTICS MARKET DYNAMICS
FIGURE 7. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 10. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 12. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ALZHEIMER’S THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. ALZHEIMER’S THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. ALZHEIMER’S THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 6. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY NMDA [N-METHYL-D-ASPARTATE] RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 9. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 11. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY NMDA RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 17. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 32. CANADA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 33. CANADA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 34. CANADA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 35. CANADA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 36. MEXICO ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. MEXICO ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. MEXICO ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 39. MEXICO ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 45. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. AUSTRALIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. AUSTRALIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 52. AUSTRALIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 54. CHINA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. CHINA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56. CHINA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 57. CHINA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 58. INDIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. INDIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 60. INDIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 61. INDIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 62. INDONESIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. INDONESIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. INDONESIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 66. JAPAN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. JAPAN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. JAPAN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 69. JAPAN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 70. MALAYSIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. MALAYSIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72. MALAYSIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 74. PHILIPPINES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. PHILIPPINES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. PHILIPPINES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 78. SINGAPORE ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. SINGAPORE ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. SINGAPORE ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 82. SOUTH KOREA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. SOUTH KOREA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. SOUTH KOREA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 86. TAIWAN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. TAIWAN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88. TAIWAN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 90. THAILAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. THAILAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. THAILAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 93. THAILAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 94. VIETNAM ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. VIETNAM ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. VIETNAM ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 103. DENMARK ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. DENMARK ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. DENMARK ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 106. DENMARK ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 107. EGYPT ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. EGYPT ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 109. EGYPT ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 110. EGYPT ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 111. FINLAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. FINLAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113. FINLAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 114. FINLAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 115. FRANCE ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. FRANCE ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. FRANCE ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 118. FRANCE ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 119. GERMANY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. GERMANY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 121. GERMANY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 122. GERMANY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 123. ISRAEL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. ISRAEL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 125. ISRAEL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 127. ITALY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. ITALY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. ITALY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 130. ITALY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 131. NETHERLANDS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. NETHERLANDS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 133. NETHERLANDS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 135. NIGERIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. NIGERIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. NIGERIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 139. NORWAY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. NORWAY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. NORWAY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 142. NORWAY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 143. POLAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. POLAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 145. POLAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 146. POLAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 147. QATAR ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. QATAR ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 149. QATAR ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 150. QATAR ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 163. SPAIN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. SPAIN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 165. SPAIN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 166. SPAIN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 167. SWEDEN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. SWEDEN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 169. SWEDEN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 171. SWITZERLAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 172. SWITZERLAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 173. SWITZERLAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 175. TURKEY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. TURKEY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 177. TURKEY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 178. TURKEY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 187. ALZHEIMER’S THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 188. ALZHEIMER’S THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 189. ALZHEIMER’S THERAPEUTICS MARKET LICENSE & PRICING

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • AC Immune SA
  • Acadia Pharmaceuticals Inc.
  • Alnylam Pharmaceuticals, Inc.
  • AlzeCure Pharma AB
  • Alzheon, Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Cassava Sciences, Inc.
  • Cognition Therapeutics, Inc.
  • Corium, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Grifols S.A.
  • H. Lundbeck A/S
  • Luye Pharma Group Ltd.
  • Merz Pharma GmbH & Co. KGaA
  • NeuroVision Imaging, Inc.
  • Novartis AG
  • Oryzon Genomics, S.A.
  • Pfizer, Inc.
  • Siemens Healthcare GmbH
  • Synaptogenix, Inc.
  • TauRx Pharmaceuticals Ltd.
  • VTV Therapeutics

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages196
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 6.66 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.96 Billion
Compound Annual Growth Rate8.6%
Regions CoveredGlobal

Related Topics

Related Reports

Alzheimer's Drugs Global Market Report 2024 - Product Image

Alzheimer's Drugs Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Alzheimer's Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Alzheimer's Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From
Alzheimer's Drugs Market Report by Drug Class, Drug Type, Distribution Channel, Region and Company Analysis 2024-2032 - Product Image

Alzheimer's Drugs Market Report by Drug Class, Drug Type, Distribution Channel, Region and Company Analysis 2024-2032

  • Report
  • 225 Pages
  • Global
From
Global Alzheimer's Drugs Market Report by Drug Class, Distribution Channel, and Region 2024-2032 - Product Image

Global Alzheimer's Drugs Market Report by Drug Class, Distribution Channel, and Region 2024-2032

  • Report
  • 137 Pages
  • Global
From
Alzheimer's Disease Therapeutics Market 2024-2028 - Product Image

Alzheimer's Disease Therapeutics Market 2024-2028

  • Report
  • 168 Pages
  • Global
From

About the Market

The Alzheimer Disease Clinical Trial market is a subset of the larger Alzheimer's Disease Drugs market. It is composed of clinical trials conducted to evaluate the safety and efficacy of drugs for the treatment of Alzheimer's Disease. These trials are conducted by pharmaceutical companies, research institutions, and other organizations. The trials involve recruiting participants, administering the drug, and collecting data on the effects of the drug. The results of the trials are then used to determine whether the drug is safe and effective for treating Alzheimer's Disease. The Alzheimer Disease Clinical Trial market is highly competitive, with many companies vying for a share of the market. Companies in the market include AbbVie, Biogen, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.